AnaptysBio saw the highest growth of 0.99% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of AnaptysBio’s patent filings and grants. Buy the databook here.
AnaptysBio has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 100% grants. The United States(US), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where AnaptysBio is filings its patents. Among the top granted patent authorities, AnaptysBio has 100% of its grants in United States(US).
Regeneron Pharmaceuticals could be the strongest competitor for AnaptysBio
Patents related to climate change and rare diseases lead AnaptysBio's portfolio
AnaptysBio has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead AnaptysBio portfolio followed by leukemia, and testicular cancer
AnaptysBio has highest number of patents in breast cancer followed by leukemia, testicular cancer, gastrointestinal tract cancer, and esophageal cancer. For breast cancer, nearly 2% of patents were filed and 6% of patents were granted in Q2 2024.
For comprehensive analysis of AnaptysBio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.